Literature DB >> 15890642

Engineering conformational destabilization into mouse apolipoprotein E. A model for a unique property of human apolipoprotein E4.

Danny M Hatters1, Clare A Peters-Libeu, Karl H Weisgraber.   

Abstract

Apolipoprotein (apo) E4 is a major risk factor for Alzheimer and cardiovascular diseases. ApoE4 differs from the two other common isoforms (apoE2 and apoE3) by its lower resistance to denaturation and greater propensity to form partially folded intermediates. As a first step to determine the importance of stability differences in vivo, we reengineered a partially humanized variant of the amino-terminal domain of mouse apoE (T61R mouse apoE) to acquire a destabilized conformation like that of apoE4. For this process, we determined the crystal structure of wild-type mouse apoE, which, like apoE4, forms a four-helix bundle, and identified two structural differences in the turn between helices 2 and 3 and in the middle of helix 3 as potentially destabilizing sites. Introducing mutations G83T and N113G at these sites destabilized the mouse apoE conformation. The mutant mouse apoE more rapidly remodeled phospholipid than T61R mouse apoE, which supports the hypothesis that a destabilized conformation promotes apoE4 lipid binding.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890642     DOI: 10.1074/jbc.M503910200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles.

Authors:  Irina N Gorshkova; David Atkinson
Journal:  Biochemistry       Date:  2011-02-20       Impact factor: 3.162

Review 2.  Understanding the basis for the association of apoE4 with Alzheimer's disease: opening the door for therapeutic approaches.

Authors:  Ning Zhong; Karl H Weisgraber
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

3.  Structure-based reassessment of the caveolin signaling model: do caveolae regulate signaling through caveolin-protein interactions?

Authors:  Brett M Collins; Melissa J Davis; John F Hancock; Robert G Parton
Journal:  Dev Cell       Date:  2012-07-17       Impact factor: 12.270

4.  Concerning the structure of apoE.

Authors:  Carl Frieden; Kanchan Garai
Journal:  Protein Sci       Date:  2013-10-19       Impact factor: 6.725

5.  Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.

Authors:  Hung-Kai Chen; Zhaoping Liu; Anke Meyer-Franke; Jens Brodbeck; Rene D Miranda; James G McGuire; Michael A Pleiss; Zhong-Sheng Ji; Maureen E Balestra; David W Walker; Qin Xu; Dah-eun Jeong; Madhu S Budamagunta; John C Voss; Stephen B Freedman; Karl H Weisgraber; Yadong Huang; Robert W Mahley
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

6.  Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia.

Authors:  Irina N Gorshkova; Kyriakos E Kypreos; Donald L Gantz; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

Review 7.  The helix bundle: a reversible lipid binding motif.

Authors:  Vasanthy Narayanaswami; Robert S Kiss; Paul M M Weers
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2009-09-19       Impact factor: 2.320

8.  Structural differences between apolipoprotein E3 and E4 as measured by (19)F NMR.

Authors:  Kanchan Garai; Sourajit M Mustafi; Berevan Baban; Carl Frieden
Journal:  Protein Sci       Date:  2010-01       Impact factor: 6.725

9.  Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function.

Authors:  Ning Zhong; Gayathri Ramaswamy; Karl H Weisgraber
Journal:  J Biol Chem       Date:  2009-08-07       Impact factor: 5.157

10.  ApoE: In Vitro Studies of a Small Molecule Effector.

Authors:  Tridib Mondal; Hanliu Wang; Gregory T DeKoster; Berevan Baban; Michael L Gross; Carl Frieden
Journal:  Biochemistry       Date:  2016-04-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.